The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Key Unit of Methodology in Clinical Research, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China.
Lipids Health Dis. 2024 Jan 8;23(1):5. doi: 10.1186/s12944-024-02004-4.
Lipid management in clinic is critical to the prevention and treatment of Chronic kidney disease (CKD), while the manifestations of lipid indicators vary in types and have flexible association with CKD prognosis.
Explore the associations between the widely used indicators of lipid metabolism and their distribution in clinic and CKD prognosis; provide a reference for lipid management and inform treatment decisions for patients with non-dialysis CKD stage 3-5.
This is a retrospective cohort study utilizing the Self-Management Program for Patients with Chronic Kidney Disease Cohort (SMP-CKD) database of 794 individuals with CKD stages 3-5. It covers demographic data, clinical diagnosis and medical history collection, laboratory results, circulating lipid profiles and lipid distribution assessments. Primary endpoint was defined as a composite outcome(the initiation of chronic dialysis or renal transplantation, sustained decline of 40% or more in estimated glomerular filtration rate (eGFR), doubled of serum creatinine (SCr) from the baseline, eGFR less than 5 mL/min/1.73m, or all-cause mortality). Exposure variables were circulating lipid profiles and lipid distribution measurements. Association were assessed using Relative risks (RRs) (95% confidence intervals (CIs)) computed by multivariate Poisson models combined with least absolute shrinkage and selection operator (LASSO) regression according to categories of lipid manifestations. The best model was selected via akaike information criterion (AIC), area under curve (AUC), receiver operating characteristic curve (ROC) and net reclassification index (NRI). Subgroup analysis and sensitivity analysis were performed to assess the interaction effects and robustness..
255 individuals reached the composite outcome. Median follow-up duration was 2.03 [1.06, 3.19] years. Median age was 58.8 [48.7, 67.2] years with a median eGFR of 33.7 [17.6, 47.8] ml/min/1.73 m. Five dataset were built after multiple imputation and five category-based Possion models were constructed for each dataset. Model 5 across five datasets had the best fitness with smallest AIC and largest AUC. The pooled results of Model 5 showed that total cholesterol (TC) (RR (95%CI) (per mmol/L) :1.143[1.023,1.278], P = 0.018) and percentage of body fat (PBF) (RR (95%CI) (per percentage):0.976[0.961,0.992], P = 0.003) were significant factors of composite outcome. The results indicated that comprehensive consideration of lipid metabolism and fat distribution is more critical in the prediction of CKD prognosis..
Comprehensive consideration of lipid manifestations is optimal in predicting the prognosis of individuals with non-dialysis CKD stages 3-5.
脂质管理在慢性肾脏病(CKD)的预防和治疗中至关重要,而脂质指标的表现形式在类型上有所不同,并且与 CKD 预后具有灵活的关联。
探讨广泛使用的脂质代谢指标及其在临床中的分布与 CKD 预后之间的关系;为非透析 CKD 3-5 期患者的脂质管理提供参考,并为治疗决策提供信息。
这是一项回顾性队列研究,利用慢性肾脏病自我管理计划患者队列(SMP-CKD)数据库,纳入了 794 名 CKD 3-5 期患者。该数据库涵盖了人口统计学数据、临床诊断和病史收集、实验室结果、循环脂质谱和脂质分布评估。主要终点定义为复合结局(开始慢性透析或肾移植、估计肾小球滤过率(eGFR)持续下降 40%或以上、血清肌酐(SCr)从基线增加一倍、eGFR 小于 5ml/min/1.73m 或全因死亡率)。暴露变量为循环脂质谱和脂质分布测量值。采用多变量泊松模型结合最小绝对收缩和选择算子(LASSO)回归,根据脂质表现的类别评估关联,并计算相对风险(RR)(95%置信区间(CI))。通过赤池信息量准则(AIC)、曲线下面积(AUC)、接收者操作特征曲线(ROC)和净重新分类指数(NRI)选择最佳模型。进行亚组分析和敏感性分析,以评估交互作用和稳健性。
255 名患者达到了复合结局。中位随访时间为 2.03 [1.06, 3.19] 年。中位年龄为 58.8 [48.7, 67.2] 岁,中位 eGFR 为 33.7 [17.6, 47.8] ml/min/1.73 m。经过多次插补后建立了 5 个数据集,并为每个数据集构建了 5 个基于类别概率的泊松模型。五个数据集的模型 5 具有最佳的拟合度,AIC 最小,AUC 最大。模型 5 的汇总结果表明,总胆固醇(TC)(每 mmol/L 的 RR(95%CI):1.143[1.023,1.278],P=0.018)和体脂百分比(PBF)(每百分比的 RR(95%CI):0.976[0.961,0.992],P=0.003)是复合结局的显著因素。结果表明,综合考虑脂质代谢和脂肪分布在预测 CKD 预后方面更为关键。
综合考虑脂质表现形式是预测非透析 CKD 3-5 期患者预后的最佳方法。